212 related articles for article (PubMed ID: 15953738)
1. Assessment of renal injury in vivo.
Emeigh Hart SG
J Pharmacol Toxicol Methods; 2005; 52(1):30-45. PubMed ID: 15953738
[TBL] [Abstract][Full Text] [Related]
2. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
3. Renal Safety Pharmacology in Drug Discovery and Development.
Benjamin A; Nogueira da Costa A; Delaunois A; Rosseels ML; Valentin JP
Handb Exp Pharmacol; 2015; 229():323-52. PubMed ID: 26091646
[TBL] [Abstract][Full Text] [Related]
4. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions.
Pugsley MK
J Pharmacol Toxicol Methods; 2005; 52(1):1-5. PubMed ID: 15982903
[TBL] [Abstract][Full Text] [Related]
5. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.
Valentin JP; Bass AS; Atrakchi A; Olejniczak K; Kannosuke F
J Pharmacol Toxicol Methods; 2005; 52(1):22-9. PubMed ID: 15961324
[TBL] [Abstract][Full Text] [Related]
6. Trends in safety pharmacology: posters presented at the annual meetings of the Safety Pharmacology Society 2001-2010.
Redfern WS; Valentin JP
J Pharmacol Toxicol Methods; 2011; 64(1):102-10. PubMed ID: 21635957
[TBL] [Abstract][Full Text] [Related]
7. Methods in safety pharmacology in focus.
Pugsley MK; Gallacher DJ; Towart R; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2008; 58(2):69-71. PubMed ID: 18707009
[TBL] [Abstract][Full Text] [Related]
8. Benchmarking safety pharmacology regulatory packages and best practice.
Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
[TBL] [Abstract][Full Text] [Related]
9. A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions.
Ewart L; Milne A; Adkins D; Benjamin A; Bialecki R; Chen Y; Ericsson AC; Gardner S; Grant C; Lengel D; Lindgren S; Lowing S; Marks L; Moors J; Oldman K; Pietras M; Prior H; Punton J; Redfern WS; Salmond R; Skinner M; Some M; Stanton A; Swedberg M; Finch J; Valentin JP
J Pharmacol Toxicol Methods; 2013; 68(1):30-43. PubMed ID: 23665080
[TBL] [Abstract][Full Text] [Related]
10. Preclinical perspective of urinary biomarkers for the detection of nephrotoxicity: what we know and what we need to know.
Fuchs TC; Hewitt P
Biomark Med; 2011 Dec; 5(6):763-79. PubMed ID: 22103611
[TBL] [Abstract][Full Text] [Related]
11. Safety pharmacology--current and emerging concepts.
Hamdam J; Sethu S; Smith T; Alfirevic A; Alhaidari M; Atkinson J; Ayala M; Box H; Cross M; Delaunois A; Dermody A; Govindappa K; Guillon JM; Jenkins R; Kenna G; Lemmer B; Meecham K; Olayanju A; Pestel S; Rothfuss A; Sidaway J; Sison-Young R; Smith E; Stebbings R; Tingle Y; Valentin JP; Williams A; Williams D; Park K; Goldring C
Toxicol Appl Pharmacol; 2013 Dec; 273(2):229-41. PubMed ID: 23732082
[TBL] [Abstract][Full Text] [Related]
12. Overview of safety pharmacology.
Porsolt RD
Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.1. PubMed ID: 22294166
[TBL] [Abstract][Full Text] [Related]
13. Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview.
Picard S; Goineau S; Guillaume P; Henry J; Hanouz JL; Rouet R
Cardiovasc Toxicol; 2011 Dec; 11(4):285-307. PubMed ID: 21805209
[TBL] [Abstract][Full Text] [Related]
14. Methodological innovations expand the safety pharmacology horizon.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
[TBL] [Abstract][Full Text] [Related]
15. Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.
Bass AS; Vargas HM; Valentin JP; Kinter LB; Hammond T; Wallis R; Siegl PK; Yamamoto K
J Pharmacol Toxicol Methods; 2011; 64(1):7-15. PubMed ID: 21689769
[TBL] [Abstract][Full Text] [Related]
16. Innovation in safety pharmacology testing.
Pugsley MK; Towart R; Authier S; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2011; 64(1):1-6. PubMed ID: 21640842
[TBL] [Abstract][Full Text] [Related]
17. Origins, practices and future of safety pharmacology.
Bass A; Kinter L; Williams P
J Pharmacol Toxicol Methods; 2004; 49(3):145-51. PubMed ID: 15172010
[TBL] [Abstract][Full Text] [Related]
18. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
[TBL] [Abstract][Full Text] [Related]
19. Inclusion of Safety Pharmacology Endpoints in Repeat-Dose Toxicity Studies.
Redfern WS
Handb Exp Pharmacol; 2015; 229():353-81. PubMed ID: 26091647
[TBL] [Abstract][Full Text] [Related]
20. Toxicologic Pathology Forum Opinion Paper*: Recommendations for a Tiered Approach to Nonclinical Mechanistic Nephrotoxicity Evaluation.
Ennulat D; Ringenberg M; Frazier KS
Toxicol Pathol; 2018 Aug; 46(6):636-646. PubMed ID: 30049250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
